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Abstract
Introduction: Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost
normal endoscopic appearance of the colon, chronic watery, non-bloody diarrhoea and distinct histological abnor-
malities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incom-
plete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of micro-
scopic colitis, there is a need for evidence-based guidelines to improve the medical care of patients suffering from
this disorder.
Methods: Guidelines were developed by members from the European Microscopic Colitis Group and United
European Gastroenterology in accordance with the Appraisal of Guidelines for Research and Evaluation II instru-
ment. Following a systematic literature review, the Grading of Recommendations Assessment, Development and
Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were
developed by working groups consisting of gastroenterologists, pathologists and basic scientists, and voted upon
using the Delphi method.
Results: These guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as
evidence-based statements and recommendations on diagnostic criteria and treatment options, including oral
budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management
of microscopic colitis are provided based on evidence, expert opinion and best clinical practice.
Conclusion: These guidelines may support clinicians worldwide to improve the clinical management of patients
with microscopic colitis.
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Introduction
Microscopic colitis (MC) is an increasingly recognised
inflammatory bowel disease associated with significant
symptom burden and an impaired health-related
quality of life (HRQoL). The clinical course of MC is
variable, with chronic or recurrent mild to severe
symptoms persisting for months to years. The
prevalence of MC varies substantially between geo-
graphical regions. The two major histological subtypes
are collagenous colitis (CC) and lymphocytic colitis
(LC), but incomplete forms may occur (incomplete
MC (MCi)). The diagnosis of MC relies on the histo-
logical examination of colonic biopsies and requires
dedicated gastroenterologists, endoscopists and
histopathologists.
Several review articles have been published on var-
ious diagnostic and therapeutic aspects of MC.1–5 In
2012, the European Microscopic Colitis Group
(EMCG) proposed their first recommendations for
the diagnosis and treatment of MC.6 In 2013, MC
was included in the European consensus on the histo-
pathology of inflammatory bowel disease published on
behalf of the European Society of Pathology and the
European Crohn’s and Colitis Organisation.7
According to this particular guideline, MC is defined
as a “clinical pathological entity characterised by
chronic watery (non-bloody) diarrhoea, a normal or
almost normal endoscopic appearance of the colon,
and a distinct histologic pattern of collagenous colitis
or lymphocytic colitis”. This includes that other causes
for chronic diarrhoea such as infections or other exog-
enous factors have been ruled out by clinical routine
procedures. More recently, the Spanish Microscopic
Colitis Group and the American Gastroenterology
Associations have published first evidence-based state-
ments and recommendations using GRADE (Grading
of Recommendations Assessment, Development and
Evaluation) methodology, which is now considered as
the standard tool for the development of clinical prac-
tice guides.8,9
With persistent uncertainties and new
developments in the clinical management of MC, the
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EMCG identified the need to develop updated clinical
practical guidelines in order to increase awareness for
MC and support clinicians to improve clinical care of
MC patients in daily routine practice.
Methodology
The guideline working group
All members of EMCG were asked to participate and
an open invitation was placed on the UEG website for
several months prior to the first group meeting held in
Vienna in October 2018. Finally, the entire group con-
sisted of 32 physicians and researchers from 14
European countries, including gastroenterologists,
pathologists and basic scientists with expertise in scien-
tific methodology, evidence-based medicine and clinical
and therapeutic management of MC. A total of five
working groups were established (1: Epidemiology,
risk factors; 2: Pathogenesis; 3: Clinical manifestation,
quality of life; 4: Diagnosis, monitoring; 5; Treatment),
each consisting of a working group leader and five to
seven group members. A steering committee was estab-
lished consisting of the two coordinators (SM, AMu¨)
and the working group leaders (DG, YZ, GET,
AMKF, SW). First, a list of topics and research ques-
tions to be covered by the guidelines was created by the
steering committee based upon discussions with the
working group members on their relevance and their
potential impact on clinical practice. The final list of
research questions was formatted into the PICO
(patient, intervention, control, outcome) framework,
when appropriate.
Literature search and assessment of evidence
A formal systematic review of the literature was carried
out for each research question using MEDLINE
(accessed via PubMed), EMBASE electronic databases
and the Cochrane Database of Systematic Reviews
(Cochrane Library) and the Cochrane Central
Register of Controlled Trials from inception until
July 2019, with no restriction of languages and period-
ically updated. The search strategy and the process of
study selection categorised per research question can be
found in online Appendix A (supplementary material).
A review of the citations to identify potentially relevant
articles was also carried out. This included systematic
reviews and other documents offering a critical synthe-
sis of the scientific literature, as well as randomised
clinical trials, whenever possible.
Data on epidemiology, pathogenesis, clinical mani-
festations, diagnosis and treatment of MC were criti-
cally reviewed and meta-analyses conducted, when
applicable. The working groups followed the
GRADE methodology (https://www.gradewor
kinggroup.org/) to assess the quality of evidence of
statements/recommendations, and classified the recom-
mendations for the different clinical scenarios into four
final categories: strong recommendation for an interven-
tion (implying to do it), weak recommendation for an
intervention (implying to probably do it), weak against
an intervention (implying to probably not do it) and
strong against an intervention (implying not to do it).
The strength of recommendation (GR: strong or weak)
using the GRADE approach was only given for studies
on the accuracy of diagnostic procedures and on the
assessment of the treatment efficacy.
The level of evidence (LE) was classified in four
categories: high, moderate, low or very low quality,
based on the strict assessment of the quality of the
evidence. The quality of the evidence could be down-
graded as a result of limitations in the study design
or in its implementation, imprecision of estimates,
variability in the results, indirectness of the evidence
or publication bias; or upgraded because of a very
large magnitude of effects, a dose–response gradient
or if all the plausible biases would reduce an appar-
ent treatment effect. Moreover, the recommendations
were also based on some other factors, such as desir-
able and undesirable consequences of alternative
management strategies, variability in values and pref-
erences and the use of resources (costs). The results
of data extraction and quality of the evidence assess-
ments are summarised in Appendix B (supplementary
material).
Evolution of statements/recommendations
Based on the literature review and assessment of evi-
dence, the working groups drafted initial statements
and recommendations, which subsequently underwent
a voting process by the entire guideline group using the
Delphi method. The participants judged the statement/
recommendation based on a five-point Likert scale
(1: strongly disagree; 2: disagree; 3: neutral; 4: agree;
5: strongly agree), and suggested modifications or even
new ones. Following this process, the statements and
recommendations were revised by the working groups.
They were modified if necessary and voted on again
during a final face-to-face consensus meeting held in
Barcelona in October 2019. Statements and recommen-
dations were approved if 75% or more of the partic-
ipants agreed with it (Likert score of 4 or 5; 75% to
94%: consensus, 95% to 100%: strong consensus).
Each statement and recommendation is accompanied
by the LE (high, moderate, low, very low), grade of
recommendation, result of the vote (percentage agree-
ment) at the consensus meeting and discussion of
the corresponding evidence. The guideline group
Miehlke et al. 3
formulated a total of 39 statements and recommenda-
tions (Table 1).
Epidemiology and risk factors of MC. What is the inci-
dence of MC?
Statement 1.1: The pooled overall incidence rate of
MC is estimated to be 11.4 (95% confidence interval
(CI): 9.2–13.6) cases per 100,000 person-years. The
incidence of CC and LC ranges from 0.6 to 16.4
cases per 100,000 person-years and from 0.6 to 16.0
cases per 100,000 person-years, respectively.
LE: high; GR: not applicable; agreement: 100%,
strong consensus
Summary of evidence: epidemiological studies have
documented an increasing incidence of MC in western
countries. An overall pooled incidence rate of 11.4
(95% CI: 9.2–13.6, I2¼ 99.72%) cases of MC per
100,000 person-years was calculated based on studies
providing population-based data.10–31 Several studies
from North America20,27 and Europe14,16–18,25,26,29
reported variations in incidence rates over a 10-year
time period in the same region. They all showed an
increasing incidence in the early years, which has
reached a plateau.32 The pooled incidence rate for
CC10,11,13–24,26–31,33–36 was 4.9 (95% CI: 4.2–5.7,
I2¼ 98.3%) cases per 100,000 person-years. The
pooled LC incidence rate was 5.0 (95% CI: 4.0–6.1,
I2 98.75%) cases per 100,000 person-years.10–31
Geographic variations in the incidence of MC have
been reported; however, the limited number of studies
from Southern Europe compared to Northern Europe
and the lack of direct comparative studies from differ-
ent countries for the same time period does hinder firm
conclusions on this matter.
The MC incidence is higher in the elderly. A previ-
ous meta-analysis showed the median patients’ age at
the time of diagnosis was over 60 years old (CC: 64.9,
CI: 57.03–72.78; LC: 62.2, CI: 54.0–70.4 years).32
However, up to 25% of patients diagnosed with CC
were less than 45 years33 and cases of CC have even
been described in children.37–40
What is the prevalence of MC?
Statement 1.2: The pooled overall prevalence of MC
is estimated to be 119 (95% CI: 73–166) per 100,000
persons, with an overall prevalence of 50.1 per 100,000
person-year for CC and 61.7 per 100,000 persons
for LC.
LE: high; GR: NA; agreement: 94%, consensus
Summary of evidence: five population-based studies
from Spain,21,41 North America20,27 and Sweden30 have
assessed the prevalence of MC and provided a wide
range from 47.5 to 219 cases per 100,000 persons.
These studies were pooled to provide an overall MC
prevalence of 119.4 (95% CI: 72.9–165.9, I2¼ 97.08%)
cases per 100,000 persons. For CC, the pooled
prevalence was estimated to be 50.1 (95% CI: 13.69–
76.5, I2¼ 98.37%) cases per 100,000
persons.20,21,27,30,33,41 The estimated pooled prevalence
of LC was 61.7 (95% CI: 48.2–75.3, I2¼ 80.56%) per
100,000 persons.20,21,27,30,41 Some studies reported that
increasing age was a risk factor for developing
MC,20,33,41 with a 5.25 (95% CI: 3.81–7.24) times
higher probability of MC in people over 65 years of
age.41
What is the frequency of MC in chronic diarrhoea?
Statement 1.3: The pooled frequency of MC in
patients with unexplained chronic watery diarrhoea is
12.8% (95% CI: 10–16), with significant heterogeneity
(I2¼ 93.6%).
LE: moderate; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: the frequency of MC in
patients with chronic or intermittent watery diarrhoea
and a macroscopically normal (or near normal) colon
has been evaluated in several studies.17,18,21,26,27,42–72
Based on studies with a moderate or high quality,
and a sample size of 100 patients,17,18,21,26,27,42,43,45–
47,49,52,54,56,59,60 the pooled overall frequency of MC
was estimated to be 12.8% (95% CI: 9.9–15.9,
I2¼ 93.6%). The pooled frequency of CC and LC
was 4.96% (95% CI: 3.6–6.5,
I2¼ 85.2%)17,18,21,26,27,42,43,45,47,49,52,54,56,60 and 8.2%
(95% CI: 6.0–10.8,
I2¼ 92.0%),17,18,21,26,27,42,43,45,47,49,52,54,56,60 respective-
ly (see also Appendix D, supplementary material).
The data showed high heterogeneity and are not direct-
ly comparable, considering the different geographical
and genetic background, different definitions of chron-
ic watery diarrhoea used, the lack of clearly described
diagnostic criteria for MC and diagnostic work-up
before colonoscopy.
Is smoking a risk factor for MC?
Statement 1.4: Former, but especially current smok-
ing is associated with an increased risk for both CC
and LC.
LE: moderate; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: the prevalence of current
smoking in MC patients ranged from 15.3% to
40.7% (CC: 13.6–37.1%; LC: 13.2–26.0%) compared
to 5.0–28.2% in non-MC control groups.28,43,73–82 In a
recent meta-analysis,83 current smokers had a signifi-
cantly increased risk of MC compared with never
smokers (odds ratio (OR) 2.99; 95% CI: 2.15–4.15).83
Current smoking was more strongly associated with
CC than LC (OR 5.5, 95% CI: 3.4–8.9; OR 2.96,
95% CI: 2.0–4.3, respectively).83 Former smoking was
also associated with an increased risk (OR 1.6, 95% CI:
1.4–1.9).83 However, inter-study heterogeneity was
high or moderate for all analyses. Smoking status was
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often assessed by self-administered questionnaires or
review of medical records, and a homogeneous defini-
tion of smoking was lacking.
Is female gender a risk factor for MC?
Statement 1.5: The risk of developing CC or LC is
higher in women than in men.
LE: high; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: the incidence of MC is higher
in women than in men, as reported in a previous meta-
analysis published in 2015.32 Actually, subgroup anal-
yses on the incidence of MC by sex were possible in 19
studies.10,12–24,26–30 Female sex was significantly associ-
ated with MC (pooled OR 2.52, 95% CI: 2.28–2.79, I2
89%), with no differences between studies from
Northern Europe (pooled OR 2.48, 95% CI: 2.22–
2.78, I2 90%), Southern Europe (pooled OR 2.53,
95% CI: 1.63–3.94, I2 62%) and North America
(pooled OR 2.77, 95% CI: 2.02–3.81, I2 37%).
Subgroup analyses of CC (n¼ 18 studies)10,12–19,23,26–
30,33,35,36 and LC (n¼ 15 studies)10,12–19,23,26–30 repro-
duced these results, with a pooled OR of 3.24 (95%
CI: 3.03–3.47, I2¼ 35%) in CC and 2.06 (95% CI:
1.84–2.31, I2¼ 78%) in LC (see also Appendix D, sup-
plementary material). The proportion of females
among MC populations have been described in the
range of 52% to 86% (see supplement material, p.
28). In the three largest studies from Sweden,12
Denmark14 and the Netherlands,29 the average propor-
tion of females was approximately 72%.
Does smoking cessation influence the disease course
of MC?
Statement 1.6: There is insufficient evidence to eval-
uate the influence of smoking cessation on the disease
course.
LE: low; GR: NA; agreement: 78%, consensus
Summary of evidence: no studies directly evaluated
the effect of smoking cessation on the disease course. In
one study, the risk of developing MC declined signifi-
cantly over time (P¼ 0.017), leading to an attenuated
risk after five years after smoking cessation.73
However, compared to smokers, former smokers do
not have a significantly lower risk of MC (OR 1.44;
95% CI: 0.76–2.72).73–76,78,80,82 In two studies, current
smokers developed MC more than one decade earlier
than former or never smokers.77,84 The majority of the
studies showed no differences in terms of clinical pre-
sentation response to treatment, spontaneous remission
rates and disease recurrence or need for maintenance
treatment73,75,77,78,81,84–89 (see also Appendix D, sup-
plementary material). Only in a post-hoc analysis of
pooled data from two randomised controlled trials
(RCTs) was current smoking associated with a
decreased ability to achieve clinical remission with cor-
ticosteroid treatment (OR, 0.31; 95% CI: 0.10–0.98).90
Is drug use associated with a significant increased risk
of MC?
Statement 1.7: Chronic or frequent use of proton
pump inhibitors (PPIs), nonsteroidal anti-
inflammatory drugs (NSAIDs) or selective serotonin
reuptake inhibitors (SSRIs) is associated with an
increased risk of MC. However, this does not imply a
causal relationship.
LE: low; GR: NA; agreement: 94%, consensus
Summary of evidence: drug-induced MC was
addressed by retrospective case-control
studies54,81,82,91–100 showing an association with the
use of NSAIDs, PPIs and SSRIs. PPI use was strongly
associated with MC (OR 2.95, 95% CI: 1.82–4.80,
I2¼ 99%),54,81,82,91–96,98–100 especially when used con-
tinuously for 4–12 months (OR 4.69, 95% CI: 3.58–
6.13).98 Exposure to NSAIDs was also associated
with an increased risk of MC (OR 2.40, 95% CI:
1.99–2.89, I2¼ 88%).54,82,91–95,97–99 The combined use
with PPIs might further increase this risk.98 MC was
also associated with SSRI exposure (OR 2.98, 95% CI:
2.35–3.78, I2¼ 90%)54,81,82,91–93,95,96,98,99 (see also
Appendix D, supplementary material). It should be
stressed that different criteria for “drug exposure”
were applied and different reference populations were
considered. Moreover, the studies lack information on
the evolution of clinical symptoms after drug exposure,
withdrawal or re-challenge, hindering assessment of
causality.
Should any drug, potentially related to MC onset,
been withdrawn?
Recommendation 1.8: We suggest to consider with-
drawal of any drugs with a suspected chronological
relationship between drug introduction and onset of
diarrhoea.
LE: very low; GR: weak in favour; agreement: 97%,
strong consensus
Summary of evidence: in total, 62 case reports and
13 case-control studies97,101–159 describing drug-
induced MC were analysed to calculate the so-called
“imputability score” describing the likelihood of a
causal relationship between drug exposure and MC.
PPIs were the most reported drugs in relation to MC.
Resolution of diarrhoea and histological normalisation
after PPI withdrawal has been reported in four cases
using omeprazole,156,157 in 16 cases using lansopra-
zole111–113,119,123,124,129,138,141,142,146,150,153,154,160 and in
one case using esomeprazole.157 For rabeprazole, only
one case of clinical improvement without histological
control has been published.139 In 10
cases,111,112,138,153,154,156,157,160 switch to another PPI
did not result in recurrence of diarrhoea, which contra-
dicts the presumption of a class effect of PPI. One case-
control study clearly demonstrated that current and
recent use of NSAIDs and PPIs were associated with
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an increased risk of MC, when compared to never and
past use, especially in the case of continuous exposure
for 4–12 months.98 This observation underlines the
clinical relevance of a suspected chronological relation-
ship between drug use an onset of MC.
Do MC patients require a special program for colo-
noscopy surveillance to rule out colorectal cancer com-
pared to general population?
Recommendation 1.9: MC does not increase the risk
of colorectal cancer or adenoma. A special surveillance
colonoscopy program is not recommended.
LE: low; GR: strong in favour; agreement: 100%,
strong consensus
Summary of evidence: only a few studies examined
whether persistent chronic inflammation in MC is asso-
ciated with an increased risk of colorectal cancer
(CRC) or adenomas.60,71,80,161–169 The meta-analysis
of five case-control studies showed that MC was asso-
ciated with a reduced risk for CRC or adenoma com-
pared to controls (pooled OR 0.65, 95% CI: 0.33–1.28,
I2¼ 19%; and OR 0.49, 95% CI: 0.30–0.81, I2¼ 92%,
respectively). In a larger retrospective cohort of 547
MC patients (171 CC and 376 LC), CRC was detected
in five CC (2.82%) and five LC patients (1.33%).163
MC was negatively associated with the risk for CRC
and adenoma (OR 0.34, 95% CI: 0.16–0.73, p¼ 0.006;
and OR 0.52, 95% CI: 0.50–0.76, p< 0.001, respective-
ly), during a mean follow-up of 4.63 years.163
Pathogenesis of MC. Statement 2.1: Pathogenesis of
MC is complex and multifactorial. It may include lumi-
nal factors, immune dysregulation and genetic
predisposition.
LE: low; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: the mechanisms involved in
the development of MC are poorly understood and the
LE is scarce. It is not in the scope of this guideline to
provide in-depth information on this subject. The cur-
rent knowledge of the factors involved is briefly sum-
marised in Appendix C (supplementary material).
Clinical manifestation and quality of life. What are the
most common symptoms in MC?
Statement 3.1: The most common symptom in MC
is chronic watery, non-bloody diarrhoea, which is fre-
quently associated with concomitant symptoms includ-
ing faecal urgency, nocturnal stools and faecal
incontinence.
LE: moderate; GR: NA; agreement: 97%, strong
consensus
Summary of evidence: the predominant symptom of
MC is chronic watery, non-bloody diarrhoea, which
was reported by 84–100% of patients in 22 studies. In
one third of the cases, the onset of diarrhoea was acute
in nature,170–173 and according to a European prospec-
tive registry174 it persists for six months before diagno-
sis in 43%. Symptoms such as stool frequency, stool
consistency and overall duration of diarrhoea are
reported in a number of the studies, including a large
Danish study of 539 patients,13 in which an average of
6–7 bowel movements per day was reported. Common
concomitant symptoms included faecal urgency (55%),
nocturnal stools (35.3%) and faecal incontinence
(26.3%). Less frequent complaints with varying preva-
lences among studies are abdominal pain, weight loss
and bloating.172,173,175 A Swedish study from 2004
involving 199 patients with LC173 reported a median
weight loss of 5 (4–8) kg; however, early studies might
have included a selected population, as the awareness
for MC was lower.
Should MC be ruled out in patients fulfilling the cri-
teria for functional bowel disease with diarrhoea predom-
inant subtype?
Statement 3.2: MC diagnosis should be ruled out in
patients fulfilling the criteria for functional bowel dis-
ease, especially in presence of MC risk factors and/or in
absence of IBS (irritable bowel syndrome)-therapy
response.
LE: moderate; GR: NA; agreement: 93%, consensus
Summary of available evidence: MC shares similar
symptoms and endoscopic results with functional
bowel disorders, especially in diarrhoea-dominant irri-
table bowel syndrome and chronic functional diar-
rhoea.176–179 In two meta-analyses, the identification
of underlying MC diagnosis was reported in 9%
(95% CI: 4.5–14.9%) among patients exhibiting
diarrhoea-predominant functional disorders.176,178
However, not all studies employed the currently accept-
ed diagnostic criteria for MC, and different criteria for
defining functional bowel disorders were used, contrib-
uting to the high heterogeneity of the results.
Is the patient’s health-related quality of life
(HRQoL) impaired by MC?
Statement 3.3: HRQoL is impaired in patients with
MC, depending on the activity and severity of the dis-
ease and concomitant comorbidities
LE: moderate; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: MC can severely impact
HRQoL, with baseline HRQoL being lower than that
of patients with other intestinal and proctological dis-
orders.180 Impaired HRQoL was demonstrated in both
active CC and LC, including impact on function in
daily living, disease-related worry and well-
being.2,8,181–183 However, HRQoL can also be impaired
in patients with MC achieving clinical
remission.89,184,185
In a population-based study, 116 patients with
active CC had an impaired HRQoL compared with a
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background population, whereas patients in remission
scored similar.186 HRQoL was impaired in those with a
mean of 3 stools/day or a mean of 1 watery stool/
day. Therefore, it was proposed that remission in CC
should be defined as a mean of <3 stools per day and a
mean <1 watery stool per day during a one-week
registration.187
In a case-control study including 212 MC patients,
all four HRQoL dimensions (symptom burden, social
function, disease-related worry, general well-being)
were impaired in patients with active CC and LC.184
In a cross-sectional survey of 151 MC patients, 52
(34.4%) reported IBS-type symptoms and had higher
levels of anxiety, depression and somatisation, and
impaired quality of life.179 In another cross-sectional
survey of 129 patients with a new diagnosis of MC,
fatigue severity resulted to be associated with IBS-
type symptoms, psychological comorbidity and
impaired quality of life, with a negative correlation in
HRQoL measures.188 In a cross-sectional study includ-
ing 158 female MC patients, those with coexisting IBS-
like symptoms (55%) experienced worse psychological
well-being than those without. Also, smoking and PPI
were associated with gastrointestinal symptoms and
impaired psychological well-being in MC patients.89
HRQoL was evaluated in five RCTs including CC
patients189–194 and in two RCTs including LC
patients.192,195 In all seven RCTs, HRQoL was mark-
edly altered at baseline in both CC and LC patients,
and improved after budesonide treatment.196–198
Are there established metrics to measure disease activ-
ity and clinical remission in MC?
Statement 3.4: In the absence of a formally validated
metric of disease activity, disease activity and clinical
remission in MC should be assessed by the Hjortswang
criteria (clinical remission: mean of <3 stools per day
and a mean <1 water stool per day during a one-week
registration).
LE: moderate; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: in the absence of a reliable
biomarker, the definition of disease activity is based on
clinical disease activity. Various definitions for relapse
or clinical remission have been used in clinical trials on
MC, mainly based on stool frequency191,199–204 and
stool weight.200,202 A reduction of the mucosal inflam-
mation or thinning of the collagen layer has also been
used to assess histopathological response in
trials,195,199–201,203 but the correlation between histolo-
gy and clinical symptoms is weak.205
In a Swedish population-based survey, CC patients
with a mean of <3 stools per day and a mean of <1
watery stool/day during a one-week symptom registra-
tion had no or only mild impact on their HRQoL and
were, hence, defined as being in remission.187
In contrast, CC patients with either 3 stools/day or
1 watery stool/day had a significant impact on their
HRQoL and were, thus, defined as having active dis-
ease. This definition is often referred to as the
“Hjortswang criteria” for disease activity.
An MC Disease Activity Index (MCDAI) has been
proposed based on the same methodological principles
as was once used for the development of the Crohn’s
Disease Activity Index.206 A total of 162 MC patients
completed a symptom questionnaire and the HRQoL
questionnaire Inflammatory Bowel Disease
Questionnaire (IBDQ).180 A single investigator scored
a physician global assessment (PGA) of disease severity
on a 10-point scale based on the patients’ survey results.
Multiple linear regressions identified the following
symptoms to best predict the PGA: number of unformed
stools daily, presence of nocturnal stools, abdominal pain,
weight loss, faecal urgency and faecal incontinence. These
symptoms were then combined in a weighted formula to
create the MCDAI. The MCDAI was moderately asso-
ciated with the IBDQ (r¼0.62, p< 0.001).
Neither the “Hjortswang criteria” nor the MCDAI
have undergone formal prospective validation and they
do not fulfil the new requirements from the Food and
Drug Administration for a patient reported outcome in
clinical trials.207 However, the “Hjortswang criteria”
has been used in seven published clinical studies, of
which three were RCTs,193,195,203 which represents a
real-life external and prospective validation of the
score in clinical practice.
Diagnosis of MC. What is the endoscopic appearance
of MC?
Statement 4.1: Endoscopic findings are recognised
with increased frequency in patients with MC; howev-
er, they are non-specific.
LE: low;GR:NA; agreement: 95%, strong consensus
Summary of evidence: overall, 80 informative
articles including 1582 patients on endoscopic findings
in MC were identified, including 756 patients with CC,
779 patients with LC and 47 patients with
MC.19,23,166,208 Macroscopically visible lesions or alter-
ations were reported in 38.8% of patients in various
parts of the colon, including isolated linear ulcerations,
pseudomembranes, irregular vascular patterns, muco-
sal lacerations, erythema, oedema, nodularity and sur-
face textural alterations.
Although a larger number of publications exist for
CC, the number of published CC and LC patients is
very similar.208 Therefore, no conclusive statement can
be made as to whether or not endoscopic findings (and
which) may be more common in one or the other his-
tological subtype.
What are the criteria for the histological diagnosis
of CC?
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Statement 4.2: The histopathologic criteria of CC
are a thickened subepithelial collagenous band
10 mm combined with an increased inflammatory
infiltrate in the lamina propria. The criteria apply to
haematoxylin and eosin (HE)-stained slides.
LE: moderate; GR: NA; agreement: 89%, consensus
Summary of evidence: the original histological crite-
ria of CC have not been contested but elaborated by
few others.209 The most characteristic feature is a thick-
ened subepithelial collagenous band exceeding 10
mm.210–214 The band often has an irregular deeper
edge and may contain entrapped capillaries, red
blood cells and inflammatory cells. Focal damage of
the surface epithelium, including detachment from the
basement membrane, flattening and mucin
depletion,205,210,212,215–220 as well as an increased
number of intraepithelial lymphocytes (IELs) is
seen.210,211,215–223 This should be combined with an
inflammatory infiltrate in lamina propria of mild to
moderate degree, dominated by plasma cells and lym-
phocytes, but also includes eosinophils,205,210,213–
217,219,223–225 mast cells213 and, more rarely, neutro-
phils.212,214–216,219–221,224,226 Paneth cell metapla-
sia205,210,221,224 and occasionally cryptitis can be
seen.212,216,220,221,224,227 The biopsies should be orien-
tated vertically, since tangential sectioning can simulate
a thickened collagenous band.228
The histologic criteria are based on HE-stained sec-
tions. Supplementary stains, such as Van Gieson,
Masson Trichrome or Sirius red,219,220,229 might be
helpful since the collagenous band is highlighted. The
inter-observer reproducibility of the histological diag-
nose of CC is good.230,231
What are the criteria for the histological diagnosis of
LC?
Statement 4.3: The histopathologic criteria of LC
are an increased number of IELs 20 per 100 surface
epithelial cells combined with an increased inflamma-
tory infiltrate in the lamina propria and a not signifi-
cantly thickened collagenous band (<10 mm). The
criteria apply to HE-stained slides.
LE: moderate; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: LC was originally named in
1989,217 although described under the name MC in
1980.232 The criteria were based on HE-stained
slides.217 The most characteristic feature of LC is an
increased number of IELs in the surface epithelium
20 per 100 epithelial cells.1,3,4,7,233–244 Counting
should be performed in the surface epithelium, and
areas in close relation to lymphoid aggregates in
the lamina propria should be avoided.1 Focal and
mild damage of the surface epithelium, including
flattening, mucin depletion and vacuolisation, is
seen, although not as prominently as in
CC.1,3,167,218,220,236,237,240,242,245–248 This should be
combined with an inflammatory infiltrate in lamina
propria of a mild to moderate degree, dominated by
plasma cells and
lymphocytes,3,4,167,217,218,220,233,236,238,239,241,242,246–254
but might also include fewer eosinophils and
neutrophils.3,217,220,248,250,254,255 Occasionally,
cryptitis217,220,221,249,252,256 or Paneth cells metaplasia
is seen.221,236,241,250,252
Supplementary immunohistochemical staining
might be helpful, especially in borderline cases, since
highlighting the lymphocytes makes counting
easier.1,3,6,244,257 This might lead to over diagnosing
and it has been suggested to use higher cut-off values
when counting is performed on CD3-stained slides.258
What are the criteria for the histological diagnosis of
MCi?
Statement 4.4: MCi comprises incomplete CC (CCi;
defined by a thickened subepithelial collagenous band
>5 mm but <10 mm) and incomplete LC (LCi; defined
by >10 IELs but <20 IELs and a normal collagenous
band). Both types show a mild inflammatory infiltrate
in the lamina propria. The criteria apply to HE-stained
slides.
LE: low; GR: NA; agreement: 95%, strong
consensus
Summary of evidence: patients with symptoms of
MC not completely fulfilling the histological criteria
of CC or LC can be classified as CCi or LCi.1,6,237
Different terms have been used, including MC not oth-
erwise specified,224,259,260 MC type undesignated,261
borderline LC217 and paucicellular LC.251,262
Although the clinical characteristics of MC and MCi
seem indistinguishable,13,263,264 one study reports that a
greater proportion of patients with MCi experience
spontaneous remission.263 In CCi, the subepithelial col-
lagenous band is >5 mm but <10 mm. In LCi, >10 but
<20 IELs are required. The inflammatory infiltrate in
lamina propria is usually mild but comprises identical
cell types, as in CC and LC.
In borderline cases, it is recommended to use a sup-
plementary special stain or an immunohistochemical
staining procedure in addition to HE stains.265
Where should biopsies be taken in patients with sus-
pected MC?
Recommendation 4.5: We recommend ileocolono-
scopy with biopsies from at least the right and left
side of the colon.
LE: high; GR: strong in favour; agreement: 100%,
strong consensus
Summary of evidence: studies including a high
number of patients with simultaneous biopsies taken
from the right and left colon show characteristic histo-
logical changes of MC in both sides in 95–98%.13,23,263
Similarly, smaller studies have found high
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concordance.18,45,46,205,211,266–270 Studies without a
strict biopsy protocol reported a lower number of diag-
nostic biopsies from the left colon.214,219,229,243 Biopsies
exclusively from the rectum are not
sufficient.10,214,215,219,220
However, since a full ileocolonoscopy is indicated
for virtually all patients with chronic diarrhoea, it is
recommended to take biopsies from the right and left
side of the colon.
It may be advisable to send these in separately
labelled containers as the number of inflammatory
cells in normal surface epithelium and lamina propria
is higher in the right colon.233,271 Similarly, the normal
collagenous band has been reported to be thicker in the
sigmoid colon and rectum.226,227 Especially in border-
line cases, this may help the pathologists know that the
biopsies are from, for example, the left side where the
cellularity is usually lower, because this would support
the diagnosis if the pathologist is in doubt. For these
reasons, expert opinion among the pathologists
participating in this guideline tended towards separate
containers, although there is no firm evidence to sup-
port this.
Is histological monitoring necessary in patients
with MC?
Recommendation 4.6: We recommend against histo-
logical monitoring in patients with MC.
LE: very low; GR: strong in favour; agreement:
100%, strong consensus
Summary of evidence: histology of post-diagnostic
disease activity has been described, but histological
assessment of remission and relapse is not
standardised171,195,199,203,215,241,247,263,272–276 and corre-
lation between clinical disease activity and histologic
features is only weak.171,195,199,203,215,241,247,263,272–276
Conversion between CC and LC occurs in some stud-
ies.263,273,275 In a study of 283 patients, histological
features persisted in post-diagnostic biopsies for up to
one year in 77% with CC, 64% with LC and 45% in
MCi, of whom 6%, 9% and 18% converted to a dif-
ferent subtype, respectively. Histological features nor-
malised in approximately 10% and persisted beyond
the first year in a significant number of patients, includ-
ing those in whom diarrhoea had resolved and not
recurred.263
Is faecal calprotectin useful in MC?
Statement 4.7: Faecal calprotectin is not useful to
exclude or monitor MC.
LE: moderate; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: small studies have demon-
strated that faecal calprotectin was slightly, albeit sig-
nificantly, higher in those with MC as compared to
patients without organic cause of diarrhoea277 and
IBS.278 The predictive value was low due to a large
overlap. Wildt et al. demonstrated that faecal calpro-
tectin was increased in some but not all 21 patients with
active CC and overlapped between patients with active
and quiescent disease and normal controls.279 Further
studies demonstrated overlapping values of other faecal
biomarkers, including faecal eosinophil protein and
eosinophil cationic protein,63 faecal lactoferrin,279,280
alpha-1-antitryptin,281 and tryptase, eosinophil protein
X and myeloperoxidase.282 More studies on faecal bio-
markers in MC including calprotectin are clearly
needed.
Should patients with MC be tested for coeliac disease?
Recommendation 4.8: We recommend screening for
coeliac disease in patients with MC.
LE: high; GR: strong in favour; agreement: 100%,
strong consensus
Summary of evidence: one large prospective study
demonstrated an incidence of celiac disease in 3.3% of
patients with MC versus 0.4% in controls.283 Incidence
rates were between 2% and 4% in large cohort stud-
ies,13,284 a case-control study76 and one pathology reg-
istry including 3456 MC patients having undergone
both gastroscopy and lower endoscopy with
biopsy.285 These estimates are larger than in the back-
ground populations, albeit lower than reported in
numerous retrospective studies, mostly older case
series and incomplete cohorts.28,88,163,166,170,172,173,286–
290 Coeliac disease was mainly diagnosed by biochem-
ical testing rather than histology and most studies
screened only approximately half of the patients.
Development of MC was not associated with intake
of gluten.291
Should patients with MC be tested for bile acid
diarrhoea?
Statement 4.9: Testing for bile acid diarrhoea is
not part of routine diagnostic work-up in patients
with MC.
LE: low; GR: NA; agreement: 83%, consensus
Recommendation 4.10: Testing for bile acid diar-
rhoea can be considered in patients who experience
non-response to budesonide treatment.
LE: low; GR: strong in favour; agreement: 82%,
consensus
Summary of evidence: symptoms of MC and bile
acid diarrhoea are indistinguishable, and the two
conditions coexist.13,292,293 The diagnosis of bile acid
diarrhoea relies on radiolabelled75 selenium homotaur-
ocholic acid taurine (SeHCAT) testing. SeHCAT for
was performed in 181 of 539 patients included in a
large incidence cohort, and retention (<10%) was
reduced in 125.13 Small case series reporting a high
incidence of bile acid diarrhoea were probably biased
by referral.292,293 Active CC was associated with a
reduced ileal bile acid reuptake and normalisation of
disease activity increased retention and normalised bile
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acid synthesis.294 Whether this bile acid diarrhoea is a
consequence of inflammation in the right colon or even
terminal ileum or merely a coexisting disease per se
remains to be explored. Expression of the main bile
acid receptor was reduced in biopsies from the colon
of patients with MC.295 MC was not associated with
prior cholecystectomy.296
Treatment. Is oral budesonide effective in inducing
remission of CC?
Recommendation 5.1.1: We recommend using oral
budesonide to induce remission in patients with CC.
LE: moderate; GR: strong in favour; agreement:
100%, strong consensus
Summary of evidence:
Clinical response. A meta-analysis conducted in
2017197 included four randomised placebo-controlled
trials with a total of 161 CC patients.199–201,203 After
six to eight weeks of treatment, pooled analysis
revealed 81% (62/77) of patients treated with budeso-
nide 9 mg/d achieved a clinical response compared to
36% (30/84) of patients treated with placebo (relative
risk (RR) 2.98, 95% CI: 1.14–7.75; random-effects).
This analysis was statistically significant for heteroge-
neity (p¼ 0.001, I2¼ 81%). After excluding an outlier
with an unusually high response rate to placebo,203 the
I2 statistic decreased to 0% and the respective clinical
response rates were 81% (38/47) and 17% (8/47) (RR
4.56, 95% CI: 2.43–8.55). Secondary end points in that
study203 included assessing clinical remission at eight
weeks according to the Hjortswang criteria of disease
activity (mean <3 stools per day, with <1 watery stool
per day). The inclusion of this study in the meta-
analysis using these data resulted in a pooled clinical
remission rate of 81% (62/77) for budesonide com-
pared to 26% (22/84) with placebo (RR 3.10, 95%
CI: 1.8–5.3; random effects). There was no significant
heterogeneity (p¼ 0.186; I2¼ 37.7%) (see also
Appendix D, supplementary material).
Histological response. The pooled analysis of histo-
logical response of the four studies197 included a total
of 161 patients with histological remission occurring in
60/77 (78%) and 27/84 (32%) of patients receiving
budesonide and placebo, respectively (RR 2.68, 95%
CI: 1.37–5.24), which did demonstrate a statistically
significant response.
Quality of life. In one study,201 the validated
Gastrointestinal Quality of Life Index (GIQLI) was
used to measure quality of life at baseline and after
six weeks of treatment with budesonide or placebo.
A complete quality of life assessment was calculated
for 29 trial participants (budesonide: n¼ 17; placebo:
n¼ 12). The mean baseline GIQLI score was 67 in the
budesonide group and 86 in the placebo group. After
six weeks of treatment, the mean GIQLI score
remained unchanged in the placebo group (86 to 88)
but increased significantly in the budesonide group
(67 to 92; p< 0.001).
Is oral budesonide effective in inducing remission
of LC?
Recommendation 5.1.2: We recommend using oral
budesonide to induce remission in patients with LC.
LE: low; GR: strong in favour; agreement: 100%,
strong consensus
Summary of evidence:
Clinical response. A pooled analysis for clinical
response in three studies192,195,297 shows a statistically
significant benefit for budesonide over placebo. Clinical
remission was noted in 84% (43/51) of budesonide
patients and 43% (19/44) of placebo patients (RR
1.89, 95% CI: 1.3–2.7), without heterogeneity
(I2¼ 0%) (see also Appendix D, supplementary
material).
Histological response. The pooled analysis for his-
tological response showed a statistically significant ben-
efit for budesonide over placebo. Histological response
was noted in 78% of budesonide patients compared to
33% of placebo patients (two studies; 39 participants;
RR 2.44, 95% CI: 1.13–5.28, I2¼ 0%).196
Quality of life. The 36-item Short Form Health
Survey scores at baseline were reduced compared to
normal values for both the physical and mental
domains. In the budesonide group, the mean physical
sum score increased from 42.0 at baseline to 49.7 after
six weeks of treatment, while the mean mental sum
score was unchanged, with a value of 46.5 at baseline
and 46.9 after six weeks192 In the placebo group, the
mean physical sum score increased from 44.1 at base-
line to 48.0 after six weeks of treatment, while the mean
mental sum score was unchanged, with a value of 49.0
at baseline and 49.1 after six weeks.192
Is oral budesonide effective for maintaining remission
of CC?
Recommendation 5.2.1: We recommend using oral
budesonide to maintain remission in patients with CC.
LE: moderate; GR: strong in favour; agreement:
94%, consensus
Summary of evidence:
Maintenance of clinical response. In three stud-
ies,191,193,272 patients with CC who had achieved a clin-
ical response with open-label budesonide were
randomised to continuous treatment with budesonide
or placebo. A pooled analysis of the three studies
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showed that 68% (57/84) of patients receiving budeso-
nide maintained remission at their respective study end-
points, whereas only 20% (18/88) of patients receiving
placebo maintained remission (RR 3.30, 95% CI: 2.13–
5.09).197 At the end of six months, more patients
assigned to budesonide than placebo had maintained
their clinical response (75% vs 25%). Results from two
randomised clinical trials showed that maintenance
therapy with budesonide 6 mg daily over six months
resulted in a lower risk of clinical relapse (RR 0.34,
95% CI: 0.19–0.6).197 A lower dose of budesonide (3
mg daily alternating with 6 mg daily) over 12 months
showed similar efficacy in maintaining clinical response
(see also Appendix D, supplementary material). In a
retrospective study on 75 patients with CC, only 20%
required budesonide doses of 6 mg/d or more to main-
tain clinical remission.85
Maintenance of histological response. In two stud-
ies,191,272 25 patients assigned to budesonide with a
maintained clinical response underwent a follow-up
colonoscopy or sigmoidoscopy at the end of six
months of treatment. Of these, 19 patients had also
maintained their histological response, representing
48% (19/40) of the initial patient cohort randomised
to budesonide. In comparison, 19 patients assigned to
placebo with a maintained clinical response also under-
went a follow-up colonoscopy or sigmoidoscopy at the
end of six months of treatment. Six of these patients,
representing 15% (6/40) of the initial patient cohort
randomised to placebo, had a maintained histological
response. The pooled RR for maintenance of histolog-
ical response was 3.17 (95% CI: 1.44–6.95). This was
not significant for heterogeneity (p¼ 0.60, I2¼ 0%).197
Is oral budesonide effective for maintaining remission
of LC?
Recommendation 5.2.2: We suggest using oral bude-
sonide to maintain remission in patients with LC.
LE: very low; GR: weak in favour; agreement: 84%,
consensus
Summary of evidence: there is no RCT assessing the
efficacy of budesonide to maintain remission in LC.
However, given the similarity of this disease with CC,
budesonide has been used to maintain remission in LC
in clinical practice. The opinion of the experts favours
the use of this drug in the maintenance of clinical
remission in LC.
Is budesonide a safe drug in the treatment of MC?
Statement 5.3.1: There is no increased risk of serious
adverse events with budesonide in MC.
LE: low; GR: NA; agreement: 100%, strong
consensus
Summary of evidence: five of seven RCTs of CC
reported the proportion of patients experiencing at
least one adverse event.191,193,201,203,272 Pooled adverse
event data, regardless of whether the study was an
induction or maintenance trial, showed no statistically
significant difference in adverse event rates between
budesonide and placebo.197 Forty-nine per cent (68/
140) of patients given budesonide and 42% (63/150)
of patients given placebo experienced at least one
adverse event (five studies, 290 patients; RR 1.18,
95% CI: 0.92–1.51). Seven per cent (10/140) and 7%
(11/150) of patients administered budesonide and pla-
cebo, respectively, withdrew due to adverse events (five
studies, 290 patients; RR 0.97, 95% CI: 0.43–2.17).
Serious adverse events were rare, with 1% (1/84) of
patients receiving budesonide and 1% (1/91) of patients
receiving placebo experiencing one (four studies, 175
patients; RR 1.11, 95% CI: 0.15–8.01).
Adverse events were reported in two RCTs of
LC.192,195 In one study, six adverse events occurred in
two patients (10%) in the budesonide group, compared
to nine adverse events in three patients (15%) in the
placebo group (RR 0.63, 95% CI: 0.12–3.41).192 In
another RCT, 47.4% (9/19) in the budesonide group
and 42.1% (8/19) in the placebo group presented
adverse events.195
Is prolonged use of oral budesonide in MC associated
with an increased risk of osteoporosis?
Statement 5.3.2: The risk of osteoporotic bone frac-
tures seems not be increased in budesonide-treated MC
patients, although prolonged use might be associated
with a decrease of bone mineral density.
LE: low; GR: NA; agreement: 97%, strong
consensus
Summary of evidence: data on the effect of long-
term budesonide on bone mineral density mainly
come from its use in other diseases. A mean dose of
budesonide of 8.5 mg/day (range, 6–9 mg/day) for two
years induced more alterations in bone mineral density
(loss >2% per year) than not receiving corticosteroid
treatment in patients with Crohn’s disease in remis-
sion.298 However, in a case-control study, treatment
with budesonide at a dose of around 3 mg/day was
not associated with an increased risk of fracture.299
Oral budesonide (6 mg/d for three years) plus urso-
deoxycholic acid to treat patients with primary biliary
cirrhosis was also associated with a decrease in bone
mass density, with no relation to the stage of liver
disease.300
One study in MC patients (n¼ 50) showed no signif-
icant differences in bone mineral density compared to a
control group (n¼ 49) of similar age and sex: 58% oste-
oporosis and osteopenia in MC versus 39% in the con-
trol group.79 However, the sample size was insufficient
and the statistical power low. The cumulative dose of
budesonide was associated with lower bone mineral
density and T-score in the hip, with a cut-off of 2500
mg of budesonide to predict osteopenia. The markers
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of bone formation P1NP (Pro-N-terminal peptide pro-
collagen type 1) and bone alkaline phosphatase were
lower in patients with MC than in controls, suggesting
an osteoblast dysfunction due to the systemic effect of
budesonide or to the disease itself. In a recent case-
control study,301 there was no increase in osteoporotic
fractures in general, but a modest isolated effect of
budesonide on the risk of spinal fractures was
observed, mainly in younger patients.
Is mesalazine effective in MC?
Recommendation 5.4: We recommend against treat-
ment with mesalazine in patients with MC for induc-
tion of remission. There are no studies for
maintenance.
LE: low; GR: strong against; agreement: 94%,
consensus
Summary of evidence: mesalazine has been shown in
placebo-controlled, randomised studies to lack efficacy
and to be inferior to treatment with budesonide in
CC203 and LC.195 Remission rates were 80%, 44%
and 38% after eight weeks of treatment with budeso-
nide, mesalazine and placebo, respectively, in patients
with CC,203 and 79%, 63% and 42%, respectively, in
patients with LC.195 These findings are supported by
real-life experience in larger cohorts reporting clinical
response to mesalazine in 4/28 with CC, 1/9 with LC
and 1/6 with MCi13 in 15 of 33 with LC170 and in 12 of
31 with CC.173 Others case series reported response to
mesalazine in about half of patients with CC and
LC.272,302–304 By contrast, mesalazine was effective in
almost all patients in an open-label mesalazine þ/- cho-
lestyramine trial.305
Is there a role for bismuth subsalicylate in MC?
Recommendation 5.5: There is not enough evidence
to recommend bismuth subsalicylate in patients
with MC.
LE: very low; GR: strong against; agreement: 92%,
consensus
Summary of evidence: the effect of treatment with
bismuth subsalicylate for eight weeks was studied in
one open-label study with 13 patients with LC or
CC.274 Clinical remission was reported in 11 and his-
tological abnormalities resolved in nine of 13. An effect
of bismuth in 10 of 55 patients with LC (45.5%) and in
21 of 76 patients with CC (63.6%) was reported in a
retrospectively collected case series.302 A total of 23%
of 22 patients with LC identified retrospectively
reported cessation of diarrhoea,288 but the histological
criteria were 10 IELs per 100 epithelial cells.
Is there a role for loperamide in MC?
Recommendation 5.6: There is not enough evidence
to recommend the use of loperamide in MC. Given the
documented effect in patients with chronic diarrhoea,
the expert’s opinion favours the use of this drug in mild
disease.
LE: very low; GR: strong in favour; agreement:
100%, strong consensus
Summary of evidence: two large retrospective case
series reported response or remission in 49 of 69
patients with CC173 and in 47 of 67 patients with
LC.170 A large retrospective cohort of 539 patients
with MC reported a subjective effect of loperamide in
46/77 with MC.13 Several cohorts or smaller series
reported complete or near complete relief of diarrhoea
in 18–57% patients with MC treated with lopera-
mide.288,304 Loperamide has proven efficacious and
safe in several randomised, placebo-controlled trials
in patients with chronic diarrhoea, in particular abol-
ishing faecal incontinence.306–309
Are bile acid binding agents effective in MC?
Recommendation 5.7: In patients with MC and bile
acid diarrhoea we suggest treatment with bile acid
binders.
LE: very low; GR: weak in favour; agreement:
100%, strong consensus
Summary of evidence: a large, prospective cohort
study demonstrated that bile acid diarrhoea diagnosed
with SeHCAT coexists with MC with an estimated
prevalence of approximately 14%, and 84 of 167
patients treated with cholestyramine reported subjec-
tive cessation of diarrhoea.13 This concurs with two
large case series reporting the effect of cholestyramine
in 26 of 44 patients with CC170 and in 26 of 46 patients
with LC.173 An open-label controlled trial demonstrat-
ed a very high response rate to cholestyramine,305 as
did Ung et al. in CC patients both with and without
concurrent bile acid diarrhoea.293 An effect of chole-
styramine was also reported in further small case
series.273,288,302 Thus, the available data indicates that
bile acid diarrhoea coexists with MC in a substantial
number of patients, and that cholestyramine could be
efficacious in patients with coexisting MC and bile acid
diarrhoea.
Is there a role for antibiotics in MC?
Recommendation 5.9: There is not enough evidence
to recommend antibiotics for treatment of MC.
LE: very low; GR: strong against; agreement: 100%,
strong consensus
Summary of evidence: antibiotics for inducing and
maintaining remission in MC have not been investigat-
ed in controlled trials. Only a few retrospective case
series have reported the outcomes of MC after antibi-
otic treatment. In a retrospective series of 161 CC
patients, various antibiotics (metronidazole, erythro-
mycin and penicillin) showed response rates of up to
60%.170 In another retrospective cohort series of 199
patients with LC, 14/23 and 2/5 responded to metroni-
dazole and norfloxacin.173 In both studies, no informa-
tion about response definition, concomitant treatment,
dosing or relapse rate were reported. Finally, in a large
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consecutive cohort of 539 patients with MC, 6/33
patients had response to antibiotics; however, effect
measurement was not defined, and treatment duration
and antibiotics of choice not reported.13
Is there a role for probiotics in MC?
Recommendation 5.10: We recommend against use
of probiotics for treatment of MC.
LE: low; GR: strong against; agreement: 100%,
strong consensus
Summary of evidence: only one placebo-controlled
trial examining probiotics against placebo has been
published. In an induction study with sample size¼ 29,
Lactobacillus acidophilus and Bifidobacterium animalis
subs Lactis were not superior to placebo.194 In another
randomised but open-labelled trial, the effect of the
probiotic VSL#3 versus mesalazine was examined.
Twenty-four patients fulfilled the study. In the
VSL#3 group, a significant reduction in stool weight
at eight weeks was demonstrated (p¼ 0.03) but no
change was seen in stool frequency.310
Is there a role for prednisolone in MC?
Recommendation 5.11: We recommend against the
use of prednisolone or other corticosteroids than bude-
sonide for the treatment of MC.
LE: low; GR: strong against; agreement: 100%,
strong consensus
Summary of evidence: only one placebo-controlled
trial with prednisolone exists. Treatment duration was
very short, sample size low (12 patients) and predniso-
lone was without significant effect.202 In one open small
trial and in several retrospective cohort studies, a pos-
itive effect of prednisolone has been reported; however,
relapse rates were high.170,173,288,311,312 An open-label
retrospective study investigated beclomethasone dipro-
pionate as a synthetic corticosteroid with topical colon-
ic release in 30 patients with MC showing a response
rate of 80% and remission rate of 67%.313
Is there a role for immunomodulators and biologics in
the treatment of patients with MC?
Recommendation 5.12: We recommend treatment
with thiopurines, anti-tumor necosis factor (TNF)
drugs or vedolizumab in selected patients with MC
who fail to respond to budesonide to induce and main-
tain clinical remission. We recommend against the use
of methotrexate in patients with MC.
LE: low; GR: strong; agreement: 97%, strong
consensus
Summary of evidence:
Azathioprine/6-mercaptopurine. The effect of thio-
purines in MC has been evaluated in several retrospec-
tive case series including from nine to 49 MC patients
who usually were steroid-dependent or -refractory. The
reported long-term response rates allowing corticoste-
roid discontinuation ranged from 28% to 89%.314–316
A retrospective analysis of 49 patients (43 on azathi-
oprine and six on mercaptopurine) demonstrated com-
plete or partial response in 43% and 22%, respectively,
whereas cessation of therapy because of adverse events
occurred in 17 patients (35%).317
Methotrexate. Methotrexate was evaluated in a ret-
rospective analysis including 19 MC patients, of whom
16 (84%) showed complete or partial clinical
response.318 Another series of 12 patients reported
complete response in seven, partial response in two
patients and no response in three patients.317 Only
one study has prospectively evaluated the effect of
methotrexate in patients intolerant or refractory to
budesonide. Here, none of the nine included patients
achieved clinical remission.319
Biologics. Anti-TNF agents in MC have been stud-
ied in small case series320,321 and single cases.322–324 In
four MC patients with severe symptoms refractory to
standard medical therapies, infliximab or adalimumab
lead to long-term clinical remission in three cases (two
with adalimumab and one with infliximab). One patient
on adalimumab had an early loss of response and was
referred for colectomy.320 Mu¨nch et al. reported three
CC patients receiving adalimumab as a third-line ther-
apy.321 Two achieved clinical remission at week six,
while one had to discontinue due to side effects, despite
clinical response. The largest series included 18 patients
(16 CC, two LC) treated with adalimumab or inflixi-
mab.323 At week 12, nine patients achieved remission
and six were responders.
Vedolizumab has been studied in an international
case series of 11 patients (five LC, six CC) who failed
to respond to other therapies including anti-TNF
agents.325 After three infusions, clinical remission was
observed in five patients (two LC and three CC), of
whom three remained well with maintenance therapy
during a median duration of 13 months. Other case
series reported successful use of vedolizumab to
induce remission of MC.326–328
Is there a role for surgery in MC?
Recommendation 5.13: Surgery can be considered in
selected patients as last option if all medical therapy
fails.
LE: very low; GR: weak; agreement: 100%, strong
consensus
Summary of evidence: scientific evidence on surgical
treatment in MC comes only from a few case
reports.329–332 One case series published in 1995
reported on nine female CC patients who failed to
respond to medical therapies (none of them received
budesonide, immunomodulators or biologics). An
ileostomy was performed in eight patients and a sig-
moidostomy in one patient. Postoperatively, diarrhoea
16 United European Gastroenterology Journal 0(0)
ceased in all patients; however, clinical symptoms
recurred after restoration of intestinal continuity.
A case report in 2000 described a CC patient who
was treated successfully by total proctocolectomy and
ileal pouch anal anastomosis.332 In two case reports of
CC patients not responding to budesonide331 or adali-
mumab,330 symptoms improved after temporary loop
ileostomy, but recurred after restoration of bowel con-
tinuity. One case report described a CC patient under-
going colectomy after adalimumab failure, but no
outcome has been reported.320
Therapeutic management of MC. Based upon the avail-
able evidence and expert opinion, a therapeutic algo-
rithm for MC is proposed (Figure 1). This algorithm is
supported by a high level of agreement among the
guideline group (strongly agree 64.3%, agree 35.7%).
For patients with active MC oral budesonide, which is
currently the only licensed drug for treatment of MC,
should be the medical therapy of choice. In case of
chronic active disease, long-term treatment with oral
budesonide with the lowest possible dose for as long
as needed is advised. The question of budesonide with-
drawal should be discussed with the patient and decid-
ed on an individual basis. In case of long-term
budesonide treatment, supplementation with calcium/
vitamin D and monitoring of bone mineral density may
be considered on an individual basis, especially in
patients with additional risk factors for osteoporosis.
Loperamide may be used on demand if needed. In
budesonide-refractory patients and in patients requir-
ing budesonide more than 6 mg per day to maintain
clinical remission, alternative medical therapies includ-
ing immunomodulators or biologics should be
considered.
Conclusions and future perspectives
These EMCG/UEG guidelines provide evidenced-
based statements and recommendations for essential
aspects of the clinical management of MC. The main
objective and potential of these guidelines is to increase
 Active micrscopic colitis
 Avoid risk factors*
 Intolerance,
patient’s preference
Loperamide, Cholestyramine
Induction: Budesonide 9 mg daily, 6 to 8 weeks 
Induction: Budesonide 9 mg/d 
Chronic active disease
Clinical remission Clinical non-response
Clinical relapse
No relapse
Maintenance: Budesonide
low-dose (3-6 mg/d)
+/- lopermide
Chronic active disease despite
budesonide ≥6 mg/d, intolerance
*smoking, NSAID, PPI
disease
**i.e. bile acid diarrhoea, coeliac
No
maintenance
therapy
Other causes for
diarrhea identified by
new clinical work-up**
Treat
accordingly
Consider alternatives:
Loperamide, cholestyramine
(or in combination)
adalimumab, infliximab,
azathioprine/6-MP,
vedolizumab,
surgery
Figure 1. Therapeutic algorithm for microscopic colitis in clinical practice.
*Smoking, NSAID, PPI.
**E.g. bile acid diarrhoea, coeliac disease.
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awareness for a presumably under-recognised medical
condition and to improve medical care and patient out-
comes. Extensive dissemination of these guidelines is
needed to facilitate widespread use and implementation
in clinical practice. Several unmet needs have been
identified, including a better understanding of the nat-
ural course and pathophysiological mechanisms of dis-
ease, reliable non-invasive biomarkers, validated
instruments for assessment of disease activity and
new treatment modalities. These gaps should be
addressed by high-quality basic research and well-
designed clinical trials.
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